English | Russian | Kazakh
ONCOLOGY, NUCLEAR MEDICINE AND TRANSPLANTOLOGY
Case Report
Jul 26, 2026 3 2

Clinical Case: Successful Boost Infusion for Graft Hypofunction After Haploidentical Hematopoietic Stem Cell Transplantation in the Blast Phase of Primary Myelofibrosis

Aisha Adusheva Albertovna 1 * ,
Vadim Kemaykin 1,
Aizat Suleymenova 1,
Saida Yeskendirova 1,
Saltanat Dossayeva 1,
Alexandr Kolesnev 1,
Ruzal Vildanova 1,
Gulzhanat Zhunis 1,
Dina Bashayeva 1,
Tansyk Sergazina 1
1 Department of Oncohematology and Bone Marrow Transplantation, National Research Oncology Center, Astana, Kazakhstan* Corresponding Author
Oncology, Nuclear Medicine and Transplantology, 2(3), 2026, onmt024, https://doi.org/10.63946/onmt/19020
Publication date: Jul 26, 2026
Full Text (PDF)

ABSTRACT

Primary myelofibrosis is a myeloproliferative neoplasm characterized by progressive bone marrow fibrosis, splenomegaly, and cytopenic syndrome, leading to a decreased quality of life.
Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative method; however, it is associated with the risk of transplant-related complications, including graft hypofunction. This report presents a rare clinical case of graft hypofunction in a patient with primary myelofibrosis after haploidentical HSCT from a related donor (son).
Graft hypofunction is associated with high transplant-related mortality due to infectious complications and hemorrhagic syndrome.

KEYWORDS

Primary Myelofibrosis JAK2 HSCT Boost-Infusion Graft Hypofunction

CITATION (Vancouver)

Albertovna AA, Kemaykin V, Suleymenova A, Yeskendirova S, Dossayeva S, Kolesnev A, et al. Clinical Case: Successful Boost Infusion for Graft Hypofunction After Haploidentical Hematopoietic Stem Cell Transplantation in the Blast Phase of Primary Myelofibrosis. Oncology, Nuclear Medicine and Transplantology. 2026;2(3):onmt024. https://doi.org/10.63946/onmt/19020
APA
Albertovna, A. A., Kemaykin, V., Suleymenova, A., Yeskendirova, S., Dossayeva, S., Kolesnev, A., Vildanova, R., Zhunis, G., Bashayeva, D., & Sergazina, T. (2026). Clinical Case: Successful Boost Infusion for Graft Hypofunction After Haploidentical Hematopoietic Stem Cell Transplantation in the Blast Phase of Primary Myelofibrosis. Oncology, Nuclear Medicine and Transplantology, 2(3), onmt024. https://doi.org/10.63946/onmt/19020
Harvard
Albertovna, A. A., Kemaykin, V., Suleymenova, A., Yeskendirova, S., Dossayeva, S., Kolesnev, A., . . . Sergazina, T. (2026). Clinical Case: Successful Boost Infusion for Graft Hypofunction After Haploidentical Hematopoietic Stem Cell Transplantation in the Blast Phase of Primary Myelofibrosis. Oncology, Nuclear Medicine and Transplantology, 2(3), onmt024. https://doi.org/10.63946/onmt/19020
AMA
Albertovna AA, Kemaykin V, Suleymenova A, et al. Clinical Case: Successful Boost Infusion for Graft Hypofunction After Haploidentical Hematopoietic Stem Cell Transplantation in the Blast Phase of Primary Myelofibrosis. Oncology, Nuclear Medicine and Transplantology. 2026;2(3), onmt024. https://doi.org/10.63946/onmt/19020
Chicago
Albertovna, Aisha Adusheva, Vadim Kemaykin, Aizat Suleymenova, Saida Yeskendirova, Saltanat Dossayeva, Alexandr Kolesnev, Ruzal Vildanova, Gulzhanat Zhunis, Dina Bashayeva, and Tansyk Sergazina. "Clinical Case: Successful Boost Infusion for Graft Hypofunction After Haploidentical Hematopoietic Stem Cell Transplantation in the Blast Phase of Primary Myelofibrosis". Oncology, Nuclear Medicine and Transplantology 2026 2 no. 3 (2026): onmt024. https://doi.org/10.63946/onmt/19020
MLA
Albertovna, Aisha Adusheva et al. "Clinical Case: Successful Boost Infusion for Graft Hypofunction After Haploidentical Hematopoietic Stem Cell Transplantation in the Blast Phase of Primary Myelofibrosis". Oncology, Nuclear Medicine and Transplantology, vol. 2, no. 3, 2026, onmt024. https://doi.org/10.63946/onmt/19020

REFERENCES

  1. Tefferi A. Primary myelofibrosis: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(1):126-132. https://doi.org/10.1002/ajh.24402
  2. Barbui T, Thiele J, Gisslinger H, Philadelphia-negative classical myeloproliferative neoplasms. Blood. 2018;131(2):171-181.
  3. Arber DA, Orazi A, Hasserjian R. The 2016 WHO classification of myeloid neoplasms. Blood. 2016;127(20):2391-2405.https://doi.org/10.1182/blood-2016-03-643544
  4. Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of myeloproliferative neoplasms. Blood. 2017;129(6):667-679.https://doi.org/10.1182/blood-2016-10-695940
  5. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy. N Engl J Med. 2012;366(9):799-807.https://doi.org/10.1056/NEJMoa1110556
  6. Tefferi A, Guglielmelli P. Myelofibrosis treatment algorithm 2018. Blood Cancer J. 2019;9(4):353-365.
  7. Passamonti F, Cervantes F, Vannucchi AM. Dynamic International Prognostic Scoring System (DIPSS). Blood. 2010;115(9):1703-1708.https://doi.org/10.1182/blood-2009-09-245837
  8. McLornan DP, Szydlo R, Robin M. Outcome of patients with myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT. Br J Haematol. 2018;182(3):418-422.https://doi.org/10.1111/bjh.15407
  9. McLornan DP, Hernandez-Boluda JC, Czerw T. Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. Leukemia. 2021;35(9):2445-2459.https://doi.org/10.1038/s41375-021-01294-2
  10. Hernández-Boluda JC, Pereira A, Kröger N. Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. Leukemia. 2021;35(1):215-224.https://doi.org/10.1038/s41375-020-0815-z
  11. Moscardo F, Romero S, Sanz J. T cell-depleted related HLA-mismatched peripheral blood stem cell transplantation as salvage therapy for graft failure after single unit unrelated donor umbilical cord blood transplantation. Biol Blood Marrow Transplant 2014;20:1060-3.https://doi.org/10.1016/j.bbmt.2014.03.024
  12. Park JA, Koh KN, Choi ES. Successful rescue of early graft failure in pediatric patients using T-cell-depleted haploidentical hematopoietic SCT. Bone Marrow Transplant 2013;49:270-5.https://doi.org/10.1038/bmt.2013.163
  13. Yoshihara S, Ikegame K, Taniguchi K. Salvage haploidentical transplantation for graft failure using reducedintensity conditioning. Bone Marrow Transplant 2011;47:369-73.https://doi.org/10.1038/bmt.2011.84
  14. Kanda J, Horwitz ME, Long GD. Outcomes of a 1-day non myeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2012;47:700-5.https://doi.org/10.1038/bmt.2011.158
  15. Tang BL, Zhu XY, Zheng CC. Successful early unmanipulated haploidentical transplantation with reducedintensity conditioning for primary graft failure after cord blood transplantation in hematologic malignancy patients. Bone Marrow Transplant 2015;50:248-52.https://doi.org/10.1038/bmt.2014.250
  16. Perini GF, Kerbauy FR, Fernandes JF. Haploidentical non-myeloablative stem cell transplantation as salvage for graft failure in a patient with juvenile myelomonocytic leukemia. Pediatr Blood Cancer 2011;57:1084.https://doi.org/10.1002/pbc.23163
  17. Pagliuca S, Legendre H, Morin S. Success of haploidentical hematopoietic stem cells transplantation in the treatment of graft failure. Ann Hematol 2016;95:353-4.https://doi.org/10.1007/s00277-015-2525-6

LICENSE

Creative Commons License
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.